Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

Similar articles for PubMed (Select 24871806)

1.

A bombesin-shepherdin radioconjugate designed for combined extra- and intracellular targeting.

Fischer CA, Vomstein S, Mindt TL.

Pharmaceuticals (Basel). 2014 May 27;7(6):662-75. doi: 10.3390/ph7060662.

2.

Dual-targeting conjugates designed to improve the efficacy of radiolabeled peptides.

Kluba CA, Bauman A, Valverde IE, Vomstein S, Mindt TL.

Org Biomol Chem. 2012 Oct 7;10(37):7594-602. doi: 10.1039/c2ob26127h. Epub 2012 Aug 16.

PMID:
22898743
3.

Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.

Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F.

Nucl Med Biol. 2013 Nov;40(8):1025-34. doi: 10.1016/j.nucmedbio.2013.07.005. Epub 2013 Aug 19.

PMID:
23969085
4.

Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors.

Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwé DA, Schubiger PA, Schibli R, García Garayoa E.

Bioconjug Chem. 2008 Dec;19(12):2432-9. doi: 10.1021/bc800319g.

PMID:
19053304
5.

New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.

García Garayoa E, Schweinsberg C, Maes V, Rüegg D, Blanc A, Bläuenstein P, Tourwé DA, Beck-Sickinger AG, Schubiger PA.

Q J Nucl Med Mol Imaging. 2007 Mar;51(1):42-50.

6.

PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.

Däpp S, García Garayoa E, Maes V, Brans L, Tourwé DA, Müller C, Schibli R.

Nucl Med Biol. 2011 Oct;38(7):997-1009. doi: 10.1016/j.nucmedbio.2011.02.014. Epub 2011 Apr 21.

PMID:
21982571
7.

A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent.

La Bella R, Garcia-Garayoa E, Bahler M, Bläuenstein P, Schibli R, Conrath P, Tourwé D, Schubiger PA.

Bioconjug Chem. 2002 May-Jun;13(3):599-604.

PMID:
12009951
8.

Tumor imaging and therapy using radiolabeled somatostatin analogues.

de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP.

Acc Chem Res. 2009 Jul 21;42(7):873-80. doi: 10.1021/ar800188e.

PMID:
19445476
9.

In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.

Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, Hoffman TJ.

J Nucl Med. 2007 Aug;48(8):1327-37. Epub 2007 Jul 13.

10.

"To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.

Nock BA, Maina T, Krenning EP, de Jong M.

J Nucl Med. 2014 Jan;55(1):121-7. doi: 10.2967/jnumed.113.129411. Epub 2013 Nov 28.

11.

Preclinical evaluation of a new bombesin analog for imaging of gastrin-releasing peptide receptors.

Shirmardi SP, Gandomkar M, Maragheh MG, Shamsaei M.

Cancer Biother Radiopharm. 2011 Jun;26(3):309-16. doi: 10.1089/cbr.2010.0912. Epub 2011 Jun 28.

PMID:
21711115
12.

An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting.

Yu Z, Ananias HJ, Carlucci G, Hoving HD, Helfrich W, Dierckx RA, Wang F, de Jong IJ, Elsinga PH.

Curr Pharm Des. 2013;19(18):3329-41. Review.

PMID:
23431995
14.

Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.

Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Volkert WA, Hoffman TJ.

Anticancer Res. 2003 Jan-Feb;23(1A):63-70.

PMID:
12680195
15.

Phase I trial of technetium [Leu13] bombesin as cancer seeking agent: possible scintigraphic guide for surgery?

De Vincentis G, Scopinaro F, Varvarigou A, Ussof W, Schillaci O, Archimandritis S, Corleto V, Longo F, Delle Fave G.

Tumori. 2002 May-Jun;88(3):S28-30.

PMID:
12365378
16.

Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.

Carlucci G, Ananias HJ, Yu Z, Hoving HD, Helfrich W, Dierckx RA, Liu S, de Jong IJ, Elsinga PH.

Mol Pharm. 2013 May 6;10(5):1716-24. doi: 10.1021/mp3005462. Epub 2013 Apr 16.

PMID:
23590837
17.

Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides.

Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR.

Clin Cancer Res. 2009 Aug 15;15(16):5240-9. doi: 10.1158/1078-0432.CCR-08-3145. Epub 2009 Aug 11.

18.

Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women.

Santos-Cuevas CL, Ferro-Flores G, Arteaga de Murphy C, Pichardo-Romero PA.

Nucl Med Commun. 2008 Aug;29(8):741-7. doi: 10.1097/MNM.0b013e3282ffb45c.

PMID:
18753829
19.

The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals.

Prasanphanich AF, Lane SR, Figueroa SD, Ma L, Rold TL, Sieckman GL, Hoffman TJ, McCrate JM, Smith CJ.

In Vivo. 2007 Jan-Feb;21(1):1-16.

20.

Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles.

Rangger C, Helbok A, Sosabowski J, Kremser C, Koehler G, Prassl R, Andreae F, Virgolini IJ, von Guggenberg E, Decristoforo C.

Int J Nanomedicine. 2013;8:4659-71. doi: 10.2147/IJN.S51927. Epub 2013 Dec 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk